Status:

COMPLETED

To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.

Lead Sponsor:

GlaxoSmithKline

Conditions:

Depressive Disorder and Anxiety Disorders

Eligibility:

MALE

18-45 years

Phase:

PHASE1

Brief Summary

A study to investigate the effects GSK561679 on part of the body's system that controls the balance of many of the hormones (including cortisol).

Eligibility Criteria

Inclusion

  • Inclusion:
  • Healthy male subjects
  • non-smoker
  • normal ECG
  • Exclusion:
  • shift workers
  • vegetarians
  • persons who travel distances
  • persons participating in a psychology or psychiatry course

Exclusion

    Key Trial Info

    Start Date :

    October 6 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 8 2007

    Estimated Enrollment :

    20 Patients enrolled

    Trial Details

    Trial ID

    NCT00426608

    Start Date

    October 6 2006

    End Date

    January 8 2007

    Last Update

    September 11 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    GSK Investigational Site

    Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ